The overall objective of the Case Gl Cancer SPORE Developmental Research Program (SDRP) is to develop innovative and diverse approaches to focus on Gl Cancer translational research across the spectrum from etiology through prevention screening, diagnostics, therapeutics, and survivorship. The SPORE Developmental Research Program will provide 1) financial support, 2) Core Facility Services and 3) intellectual oversight and advice for pilot research projects and investigators. Emphasis will be placed on supporting new investigators as well as established investigators with new approaches to Gl cancers. To stimulate translational research, pilot projects with 2 Co-PI's, one basic and one clinical investigator, will be given preference. For meritorious proposals from individual basic or clinical investigators, the SDRP leadership group will identify complementary translational investigators to serve as advisors. Special plans will be instituted to stimulate Gl cancer research in new areas other than colorectal cancer. The Case Gl SPORE considers the pilot project mechanism to be an important opportunity for initiation of high risk/high impact research and will accordingly provide appropriate prioritization for such proposals. With support from the Case School of Medicine, The Case Comprehensive Cancer Center and SPORE Funds, the SDRP will support up to 4 pilot projects per year at $50,000 each. Availability of pilot projects will be announced by multiple, institution wide, electronic notice systems, by direct communication with department heads and deans and by invitations to specific scientists with exciting new approaches. Pilot proposals will be evaluated using the NIH 9 point scoring system by the SDRP Evaluation Panel composed of selected series of faculty members with involvement in Gl Cancer Research and extensive experience in NIH and other national organization peer review study sections.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Kendall, Bradley J; Rubenstein, Joel H; Cook, Michael B et al. (2016) Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol 14:1412-1419.e3
Thota, Prashanthi N; Zackria, Shamiq; Sanaka, Madhusudhan R et al. (2016) Racial Disparity in the Sex Distribution, the Prevalence, and the Incidence of Dysplasia in Barrett's Esophagus. J Clin Gastroenterol :
Parameswaran, Reshmi; Ramakrishnan, Parameswaran; Moreton, Stephen A et al. (2016) Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun 7:11154
Peyser, Noah D; Wang, Lin; Zeng, Yan et al. (2016) STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila) 9:657-63
Cui, Min; Awadallah, Amad; Liu, Wendy et al. (2016) Loss of Hes1 Differentiates Sessile Serrated Adenoma/Polyp From Hyperplastic Polyp. Am J Surg Pathol 40:113-9
Venkitachalam, Srividya; Revoredo, Leslie; Varadan, Vinay et al. (2016) Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Rep 6:23642
Fecteau, Ryan E; Kong, Jianping; Kresak, Adam et al. (2016) Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. JAMA Oncol 2:1333-1339
Sun, Xiangqing; Elston, Robert C; Barnholtz-Sloan, Jill S et al. (2016) Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiol Biomarkers Prev 25:727-35
Russo, Suzanne; Ammori, John; Eads, Jennifer et al. (2016) The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol 12:669-85
Eads, Jennifer R; Beumer, Jan H; Negrea, Lavinia et al. (2016) A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 77:333-8

Showing the most recent 10 out of 118 publications